A Phase II Trial of NeuVax Adjuvant Treatment in Node Positive and Node Negative, HER2 1+, 2+ and 3+ Breast Cancer Patients.

Trial Profile

A Phase II Trial of NeuVax Adjuvant Treatment in Node Positive and Node Negative, HER2 1+, 2+ and 3+ Breast Cancer Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2014

At a glance

  • Drugs Nelipepimut-S (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors RXi Pharmaceuticals
  • Most Recent Events

    • 30 May 2014 New trial record
    • 06 Jun 2011 The primary endpoint 'Disease-free-survival' has been met according to the Galena Biophram media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top